Market Overview

Cerulean and Daré to Host Conference Call on Proposed Transaction on March 23

Share:





Cerulean
Pharma Inc.
(NASDAQ:CERU), today announced jointly with Daré
Bioscience that the companies will hold a joint conference call to
discuss the definitive share purchase agreement under which the
stockholders of Daré Bioscience will become the majority owners of
Cerulean.

The conference call will take place at 9:00 a.m. ET on Thursday, March
23, 2017. This call can be accessed by dialing 443-637-1284 or
844-831-3031 prior to the start of the call and referencing conference
ID 91378612.

The conference call also will be webcast live over the Internet and can
be accessed on the "Investors" section of the Cerulean website, www.ceruleanrx.com.
The webcast will be archived on the Company's website until March 31,
2017.

About Daré Bioscience

Daré Bioscience is a clinical-stage pharmaceutical company focusing on
the development and commercialization of products for women's
reproductive health. Daré is committed to advancing novel clinical-stage
candidates in women's reproductive health to expand options and improve
outcomes. Product development in women's reproductive health is
fragmented creating a potential opportunity for Daré. Our goal is to
fill the gap by taking products from innovation through development –
the Daré team is well-suited to ensure these products advance and are
one day commercially available. The founders bring experience in global
women's healthcare as well as success in prior ventures in funding,
achieving regulatory approvals, partnering, and launching a number of
products, including devices, therapeutics and diagnostics. For more
information on the company, please visit www.darebioscience.com.

About Cerulean Pharma

Cerulean is a company focused on applying the Dynamic Tumor Targeting™
Platform to create nanoparticle-drug conjugates (NDCs) designed to
selectively attack tumor cells, reduce toxicity by sparing the body's
normal cells, and enable therapeutic combinations.

Additional Information about the Proposed Transaction and Where to
Find It

In connection with the proposed Daré transaction, Cerulean intends to
file relevant materials with the Securities and Exchange Commission (the
"SEC"), including a definitive proxy statement on Schedule 14A (the
"Proxy Statement"). The Proxy Statement will be sent or given to the
stockholders of Cerulean and will contain important information about
the proposed transaction and related matters. BEFORE MAKING ANY VOTING
DECISION, CERULEAN'S STOCKHOLDERS ARE URGED TO READ THE PROXY STATEMENT
AND THOSE OTHER MATERIALS (INCLUDING ANY AMENDMENTS OR SUPPLEMENTS
THERETO) CAREFULLY AND IN THEIR ENTIRETY WHEN THEY BECOME AVAILABLE
BECAUSE THEY WILL CONTAIN IMPORTANT INFORMATION ABOUT THE PROPOSED
TRANSACTION AND THE PARTIES TO THE PROPOSED TRANSACTION. The Proxy
Statement and other relevant materials (when they become available), and
any other documents filed by Cerulean with the SEC, may be obtained free
of charge at the SEC's website at www.sec.gov.
In addition, security holders will be able to obtain free copies of the
proxy statement by directing a written request to: Cerulean Pharma Inc.,
35 Gatehouse Drive, Waltham, MA, Attention: Corporate Secretary.

Participants in the Solicitation

Cerulean, Daré, and each of their respective directors and executive
officers may be deemed to be participants in the solicitation of proxies
from the stockholders of Cerulean in connection with the proposed
transaction described herein. Information regarding the interests of
these directors and executive officers in the proposed transaction
described herein will be included in the Proxy Statement described above.
Additional information regarding the directors and executive
officers of Cerulean is included in proxy statement for its 2016 Annual
Meeting, which was filed with the SEC on April 28, 2016, and is
supplemented by other public filings made, and to be made, with the SEC
by Cerulean.

View Comments and Join the Discussion!
 
Don't Miss Any Updates!
News Directly in Your Inbox
Subscribe to:
Benzinga Premarket Activity
Get pre-market outlook, mid-day update and after-market roundup emails in your inbox.
Market in 5 Minutes
Everything you need to know about the market - quick & easy.
Fintech Focus
A daily collection of all things fintech, interesting developments and market updates.
Thank You

Thank you for subscribing! If you have any questions feel free to call us at 1-877-440-ZING or email us at vipaccounts@benzinga.com